Misplaced Pages

This is an old revision of this page, as edited by 68.154.15.152 (talk) at 23:10, 15 January 2006. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Duloxetine hydrochloride (brand names: Cymbalta/Yentreve) is a medically used drug that primarily targets major depressive disorders (MDD), pain related to diabetic peripheral neuropathy and stress urinary incontinence (SUI). Known also as LY248686, chemically (+)-(S)-N-methyl-3-(1-naphthyloxy)-
2-thiophenepropanamine, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE and 5-HT transport sites. Its behavior contrasts to most other dual-reuptake inhibitors in that Ki values are nearly 1:1.

Furthermore, duloxetine lacks affinity for monoamine receptors within the central nervous system. While there is limited data available regarding the pharmacokinetic profile of duloxetine in humans, its half-life is reported to be 10 to 15 hours. Most common side effects in clinical trials were nausea, somnolence, and dry mouth. In clinical trials weight gain was neutral compared to placebo. On going studies including a 52 week safety and efficacy trial are available at www.lillytrials.com. Long-term side-effects seen in these trials did not vary from the original approval studies.

Duloxetine is also approved by the FDA for the treatment of diabetic neuropathy. Approved dosages for treatment diabetic peripheral neuropathic pain are 60mg and 120mg once daily.

When used for the treatment of depression, the approved dosage is 40mg-60 mg once daily. Duloxetine is availble in capsules of 20mg, 30mg, and 60mg.

External links

• Manufacturer website
• Duloxetine - medlineplus.org
• Prescribing Guide

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Serotonin-norepinephrine reuptake inhibitors
• Pharmacology stubs